KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) EBIT Margin (2016 - 2025)

Inovio Pharmaceuticals' EBIT Margin history spans 16 years, with the latest figure at 38336.97% for Q1 2025.

  • For Q1 2025, EBIT Margin changed N/A year-over-year to 38336.97%; the TTM value through Sep 2025 reached 49202.88%, up 950679.0%, while the annual FY2024 figure was 51616.91%, 3431664.0% down from the prior year.
  • EBIT Margin for Q1 2025 was 38336.97% at Inovio Pharmaceuticals, down from 17410.77% in the prior quarter.
  • Across five years, EBIT Margin topped out at 390.61% in Q3 2022 and bottomed at 44876.83% in Q4 2022.
  • The 5-year median for EBIT Margin is 20553.16% (2021), against an average of 23434.95%.
  • The largest YoY upside for EBIT Margin was 2016255bps in 2022 against a maximum downside of -3230307bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 12573.76% in 2021, then plummeted by -257bps to 44876.83% in 2022, then soared by 41bps to 26686.29% in 2023, then soared by 35bps to 17410.77% in 2024, then plummeted by -120bps to 38336.97% in 2025.
  • Per Business Quant, the three most recent readings for INO's EBIT Margin are 38336.97% (Q1 2025), 17410.77% (Q4 2024), and 32945.87% (Q2 2024).